Phosphoantigen-Butyrophilin complex (null)

The phosphoantigen-butyrophilin complex is a multi-component membrane receptor system enabling human Vγ9Vδ2 γδ T cells to sense intracellular metabolic disturbances caused by infection or malignancy. Phosphoantigens (PAgs), such as isopentenyl pyrophosphate (IPP) and HMBPP, bind to the intracellular domain (B30.2) of BTN3A1; this induces conformational change and facilitates assembly with BTN2A1, forming a composite receptor interface on the antigen-presenting cell surface[5][1][3]. The assembled complex serves as a ligand and activation signal for Vγ9Vδ2 T cell receptors (TCR) and can drive potent immune effector activity. This non-classical antigen sensing pathway represents a promising target for immunotherapeutic intervention in cancer and infectious diseases[3][4][5][1]. The molecular “glue” effect of phosphoantigens is unique, bridging BTN3A1 and BTN2A1 to enable T cell activation[5].

Other names

BTN3A1-BTN2A1 phosphoantigen complexγδ T cell phosphoantigen sensor complexPhosphoantigen-bound butyrophilin receptor complex

Drugs that target or influence this complex generally act by increasing cellular levels of phosphoantigens, which induce conformational changes and assembly of BTN3A1-BTN2A1 receptor complex, leading to γδ T cell activation and immune effector functions[1][3][5][4]. Experimental antibodies or molecules may block or mimic phosphoantigen-induced assembly or protein–protein interaction, modulating immune response[4][5].